MY201703A - Topical formulations comprising montelukast and combinations with mussel adhesive proteins - Google Patents

Topical formulations comprising montelukast and combinations with mussel adhesive proteins

Info

Publication number
MY201703A
MY201703A MYPI2020000043A MYPI2020000043A MY201703A MY 201703 A MY201703 A MY 201703A MY PI2020000043 A MYPI2020000043 A MY PI2020000043A MY PI2020000043 A MYPI2020000043 A MY PI2020000043A MY 201703 A MY201703 A MY 201703A
Authority
MY
Malaysia
Prior art keywords
montelukast
mussel adhesive
combinations
topical formulations
adhesive proteins
Prior art date
Application number
MYPI2020000043A
Other languages
English (en)
Inventor
Bengt Ingemar Samuelsson
Ming Gu
Original Assignee
Jiangyin Mucocare Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangyin Mucocare Pharmaceutical Co Ltd filed Critical Jiangyin Mucocare Pharmaceutical Co Ltd
Publication of MY201703A publication Critical patent/MY201703A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
MYPI2020000043A 2017-07-05 2018-07-04 Topical formulations comprising montelukast and combinations with mussel adhesive proteins MY201703A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017091819 2017-07-05
CN2018087058 2018-05-16
PCT/CN2018/094441 WO2019007356A1 (en) 2017-07-05 2018-07-04 TOPICAL FORMULATIONS COMPRISING MONTELUKAST AND COMBINATIONS WITH MOLD ADHESION PROTEINS

Publications (1)

Publication Number Publication Date
MY201703A true MY201703A (en) 2024-03-13

Family

ID=64949737

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2020000043A MY201703A (en) 2017-07-05 2018-07-04 Topical formulations comprising montelukast and combinations with mussel adhesive proteins

Country Status (13)

Country Link
US (3) US11672792B2 (cg-RX-API-DMAC7.html)
EP (1) EP3648767A4 (cg-RX-API-DMAC7.html)
JP (1) JP7288404B2 (cg-RX-API-DMAC7.html)
KR (1) KR102785243B1 (cg-RX-API-DMAC7.html)
CN (3) CN110312513B (cg-RX-API-DMAC7.html)
AU (1) AU2018295944B2 (cg-RX-API-DMAC7.html)
CA (1) CA3068818A1 (cg-RX-API-DMAC7.html)
MA (1) MA52924A (cg-RX-API-DMAC7.html)
MX (1) MX2020000029A (cg-RX-API-DMAC7.html)
MY (1) MY201703A (cg-RX-API-DMAC7.html)
SG (1) SG11201911841PA (cg-RX-API-DMAC7.html)
TW (1) TWI874298B (cg-RX-API-DMAC7.html)
WO (1) WO2019007356A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3068818A1 (en) * 2017-07-05 2019-01-10 Jiangyin Mucocare Pharmaceutical Co., Ltd Topical formulations comprising montelukast and combinations with mussel adhesive proteins
HUE062848T2 (hu) * 2018-09-14 2023-12-28 Enlitisa Shanghai Pharmaceutical Co Ltd Montelukaszt és peptidek konjugátumai
WO2020143744A1 (en) * 2019-01-10 2020-07-16 Jiangyin Mucocare Pharmaceutical Co., Ltd. New formulations containing leukotriene receptor antagonists
EP4028409A4 (en) * 2019-09-14 2023-10-11 EnliTISA (Shanghai) Pharmaceutical Co., Ltd. NEW PEPTIDES
KR20220119051A (ko) * 2019-12-02 2022-08-26 엔리티사 (상하이) 파마슈티컬 컴퍼니 리미티드 신규한 다기능성 올리고펩타이드
US20240218016A1 (en) * 2019-12-02 2024-07-04 Shenzhen Institutes Of Advanced Technology Peptides and their use in the treatment of inflammation
JP7314421B2 (ja) * 2020-02-03 2023-07-25 タロー・ファーマシューティカル・インダストリーズ・リミテッド 局所用モンテルカスト製剤
US12233055B2 (en) 2020-02-03 2025-02-25 Taro Pharmaceutical Industries Ltd. Topical Montelukast formulations
US20230372324A1 (en) 2020-10-13 2023-11-23 Diomed Developments Ltd. Gel formulations comprising montelukast
CN114588267A (zh) * 2020-12-04 2022-06-07 江苏恒瑞医药股份有限公司 一种含酰胺类局部麻醉药的药物组合物
WO2022193186A1 (en) * 2021-03-17 2022-09-22 Jiangyin Usun Pharmaceutical Co., Ltd. New diagnostic and therapeutic agents
WO2022193185A1 (en) * 2021-03-17 2022-09-22 Jiangyin Usun Pharmaceutical Co., Ltd. New conjugates
CN117794539A (zh) * 2021-08-06 2024-03-29 艾缇亚(上海)制药有限公司 免疫缺陷障碍的新治疗
CN116421547A (zh) * 2023-03-09 2023-07-14 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 一种孟鲁司特钠外用乳膏剂的制备及其在炎症性皮肤病中的应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997024112A1 (en) * 1995-12-28 1997-07-10 Yoshitomi Pharmaceutical Industries, Ltd. External preparation
US20030207932A1 (en) * 2002-05-03 2003-11-06 Morris Mann Compositions that prevent post-traumatic hyperpigmentation and methods related thereto
ES2375565T3 (es) * 2003-08-07 2012-03-02 Healor Ltd. Composiciones farmacéuticas y métodos para acelerar la cicatrización de heridas.
US6987170B1 (en) * 2004-08-09 2006-01-17 Battelle Energy Alliance, Llc Cloning and expression of recombinant adhesive protein Mefp-1 of the blue mussel, Mytilus edulis
WO2007126865A2 (en) * 2006-03-30 2007-11-08 Patrin Pharma Leukotriene antagonists via nasal drug delivery
CN1961867A (zh) * 2006-11-16 2007-05-16 徐英权 孟鲁司特钠的颗粒剂型
WO2008105803A1 (en) * 2007-02-26 2008-09-04 Larry Schlesinger Topical formulations containing leukotriene receptor antagonist and uses thereof
WO2008106081A1 (en) 2007-02-26 2008-09-04 Larry Schlesinger Topical formulations containing leukotriene receptor antagonist and use for treatment or prevention of capsular contracture, scarring or hyperpigmentation
WO2009137555A1 (en) * 2008-05-06 2009-11-12 Schlesinger S Larry Topical and injectable formulations comprising leukotriene receptor antagonist and uses thereof
CA2653011A1 (en) * 2008-12-03 2010-06-03 Apotex Technologies Inc Method and apparatus for packaging and dispensing pharmaceuticals
GB0915319D0 (en) 2009-09-03 2009-10-07 Sharma Anant Combination medicament
CN101773503A (zh) * 2010-01-12 2010-07-14 北京华禧联合科技发展有限公司 一种白三烯拮抗剂和抗组胺药组合物
ES2705244T3 (es) * 2010-06-16 2019-03-22 Inflammatory Response Res Inc Levocetirizina y montelukast para el tratamiento de la gripe y del resfriado común
CN102895661A (zh) * 2011-07-28 2013-01-30 中国科学院上海药物研究所 靶向CysLT1的药物在制备用于预防或治疗自身免疫性疾病的药物中的用途
CN104168892B (zh) 2011-12-26 2017-06-30 Sk化学公司 用于口腔施用的含有孟鲁司特或其可药用盐的膜
CN103239450B (zh) 2012-02-07 2014-11-26 齐鲁制药有限公司 一种能快速溶出、稳定的孟鲁司特钠口服固体制剂及其制备方法
ES2660494T3 (es) * 2013-03-13 2018-03-22 14779507 Uso de levocetirizina y montelukast en el tratamiento de una lesión traumática
CN103655497B (zh) * 2013-12-18 2018-05-29 北京华禧联合科技发展有限公司 一种孟鲁司特钠口腔崩解片及其制备方法
CN106573048B (zh) * 2014-08-04 2021-11-09 日东电工株式会社 体液免疫诱导促进用组合物和疫苗药物组合物
CN105769825A (zh) 2014-12-24 2016-07-20 广州朗圣药业有限公司 一种孟鲁司特钠的口腔膜剂及其制备方法
CN105878215A (zh) 2014-12-31 2016-08-24 天津康鸿医药科技发展有限公司 一种稳定的孟鲁司特口腔速溶膜及其制备方法和用途
WO2016148455A2 (ko) * 2015-03-13 2016-09-22 경희대학교 산학협력단 몬테루카스트의 생체이용률을 개선시키기 위한 방법
CN104784157B (zh) 2015-04-04 2018-06-26 齐鲁制药有限公司 一种稳定的孟鲁司特口腔薄膜剂
BR112018000953A2 (pt) * 2015-07-20 2018-09-11 Bengt I. Samuelsson Institute Of Life Science Research produto de proteína adesiva de mexilhão e aplicações do mesmo na supressão de inflamações de pele
WO2017011983A1 (zh) * 2015-07-20 2017-01-26 江阴市本特塞缪森生命科学研究院有限公司 贻贝粘蛋白用于皮肤和皮肤附属器官的防护
WO2017147067A1 (en) * 2016-02-22 2017-08-31 Board Of Regents, The University Of Texas System Antimicrobial compositions and uses thereof
US10548837B1 (en) 2016-05-04 2020-02-04 Taro Pharmaceutical Industries Ltd. Topical montelukast for treatment of atopic dermatitis
CA3068818A1 (en) * 2017-07-05 2019-01-10 Jiangyin Mucocare Pharmaceutical Co., Ltd Topical formulations comprising montelukast and combinations with mussel adhesive proteins
MA52794A (fr) * 2018-05-28 2021-04-14 Jiangyin Usun Pharmaceutical Co Ltd Nouvelle utilisation pharmaceutique
HUE062848T2 (hu) * 2018-09-14 2023-12-28 Enlitisa Shanghai Pharmaceutical Co Ltd Montelukaszt és peptidek konjugátumai
WO2020143744A1 (en) * 2019-01-10 2020-07-16 Jiangyin Mucocare Pharmaceutical Co., Ltd. New formulations containing leukotriene receptor antagonists

Also Published As

Publication number Publication date
CN113491696A (zh) 2021-10-12
WO2019007356A1 (en) 2019-01-10
EP3648767A4 (en) 2021-04-28
SG11201911841PA (en) 2020-01-30
KR20200039677A (ko) 2020-04-16
CN110312513A (zh) 2019-10-08
CA3068818A1 (en) 2019-01-10
AU2018295944B2 (en) 2023-12-14
JP2020527134A (ja) 2020-09-03
CN115300508A (zh) 2022-11-08
US20250302818A1 (en) 2025-10-02
US20210145819A1 (en) 2021-05-20
US20230404992A1 (en) 2023-12-21
EP3648767A1 (en) 2020-05-13
CN110312513B (zh) 2022-07-08
MA52924A (fr) 2021-04-28
TWI874298B (zh) 2025-03-01
US11672792B2 (en) 2023-06-13
MX2020000029A (es) 2020-08-06
TW201919633A (zh) 2019-06-01
AU2018295944A1 (en) 2020-02-20
JP7288404B2 (ja) 2023-06-07
KR102785243B1 (ko) 2025-03-26

Similar Documents

Publication Publication Date Title
MX2020000029A (es) Formulaciones topicas que comprenden montelukast y combinaciones con proteinas adhesivas del mejillon.
CA3006294A1 (en) Combinations of rapamycin and metformin for the treatment of joint and skin diseases
AU2019410432B2 (en) Quinoline derivatives for use in the treatment of inflammation diseases
SG10201808104RA (en) Cenicriviroc for the treatment of fibrosis
CR20150476A (es) Oxopyridine derivados sustituidos y su uso en el tratamiento de trastornos cardiovasculares
WO2017087608A8 (en) Modulators of ror-gamma
EA201890218A1 (ru) Ретиноидные композиции для местного применения
HK1212251A1 (en) Topical compositions and methods of use
HK1202448A1 (en) Topical formulation for administering a compound
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
WO2015171965A3 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
WO2015099838A3 (en) Compositions and methods of treating ocular diseases
WO2020128070A3 (de) Kollagenhydrolysat zur verwendung gegen hautkrankheiten und darmkrankheiten
WO2016191458A3 (en) Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment
CL2020001791A1 (es) Composiciones farmacéuticas para la piel tópicas que contienen cerdulatinib y usos de estas.
WO2015048188A3 (en) Modified fibroblast growth factors for the treatment of ocular disorders
CR20160155A (es) Tienouracilcarboxamidas cíclicas y usos de las mismas
GB201117490D0 (en) Anti-inflammatory compounds
PH12016500726B1 (en) Topical anti-inflammatory pharmaceutical composition with zileuton cream formulation
WO2020023094A3 (en) Treatment of lysosomal storage disorders
WO2014070696A3 (en) Treatment of chronic dermal inflammatory with norketotifen
WO2015068020A3 (en) Immunosuppressive treatments, formulations and methods
WO2016160574A3 (en) Aryl- and heteroaryl-pyrrolidine-2-carboxamide compounds
PH12015501538A1 (en) Topical ocular analgesic agents
WO2019132729A3 (ru) Фармацевтические композиции на основе ментилового эфира индометацина и его применение